BRIEF

on VALBIOTIS (EPA:ALVAL)

Valbiotis and Asetys form a strategic partnership

Stock price chart of VALBIOTIS (EPA:ALVAL) showing fluctuations.

Valbiotis, a French laboratory specializing in food supplements for the prevention of metabolic diseases, announces a partnership with Asetys, a recognized player in natural health solutions. Together, they aim to democratize access to these products. The market for food supplements is booming, with 61% of French people using them several times a year, and a majority looking for natural solutions.

This partnership will allow Asetys members to access reimbursements on Valbiotis products from January 7, 2025. Educational workshops will be offered to promote a proactive approach to health, strengthening prevention education. This collaboration aims to raise awareness among more patients and therapists about the benefits of natural solutions.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALBIOTIS news